Telephone sharing button Contact Us linkedin sharing button Share wechat sharing button Share mailbox sharing button info@wuxibiologics.com
arrow_left sharing button
arrow_right sharing button

Company

Vision
& Mission

Our Vision

“Every drug can be made and every disease can be treated” by building an open-access platform with the most comprehensive capabilities and technologies in the global biologics industry

Our Mission

To accelerate and transform the discovery, development and manufacturing of biologics through a comprehensive open-access platform, enabling our global healthcare partners and benefiting patients worldwide

Our Company

WuXi Biologics (stock code: 2269.HK), a Hong Kong-listed company, is a leading global open-access biologics technology platform offering end-to-end solutions to empower organizations to discover, develop, and manufacture biologics from concept to commercial manufacturing. The company’s history and achievements demonstrate its commitment to providing a truly ONE-stop service offering and strong value proposition to its global clients. With total estimated capacity for biopharmaceutical production planned in China, Ireland, the U.S., Germany, and Singapore exceeding 280,000 liters after 2023, WuXi Biologics will provide its biomanufacturing partners with a robust and premier-quality global supply chain network.  As of June 30, 2020, there were a total of 286 integrated projects , including 141 projects in pre-clinical development stage, 125 projects in early-phase (phase I and II) clinical development, 19 projects in late-phase (phase III) development and one project in commercial manufacturing.

As of June 30, 2020
141

projects in pre-clinical development stage

125

projects in early-phase clinical trials

19

projects in late-phase clinical trials

1

projects in commercial manufacturing

Culture

Integrity, Dedication, Working Together & Sharing Success

  • Put Customers First

    Exceed customers’ expectations, maximize the value for our customers, and win customers’ loyalty with a 100% customer retention rate.

  • Demonstrate Integrity

    Take the initiative to promote a positive work environment where doing the right thing is the standard. Be positive and enthusiastic, approach challenges with energy and optimism.

  • Strive for Excellence

    Pursue focus and expertise, and optimize processes in order to deliver excellent results. Relentlessly drive learning, accumulation, improvement and innovation.

  • Execute for Results

    Drive effective execution of each project and objective, focusing on solutions and results.

  • Pursue Collaboration and Teamwork

    Engage in collaboration and mutual development with an open and win-win mindset by sharing resources and leveraging the complementary advantages of each.

  • Embrace Change and Drive Innovation

    Demonstrate flexibility and ability to embrace change. Adapt quickly to transformational and innovative conditions with a strong commitment to breakthroughs and development.

History & Awards

  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
  • 2010
  • History

    January 2020 - WuXi Biologics announced to enable development of multiple neutralizing antibodies for novel coronavirus

    February 2020 - WuXi Vaccines signed long-term vaccine manufacturing contract with a global vaccine leader

    April 2020 - WuXi Biologics completed acquisition of a drug product manufacturing facility in Germany

    April 2020 - WuXi Biologics successfully completed PFS Filling at its robotic aseptic filling facility

    June 2020 - WuXi Biologics (Suzhou) received EMA GMP certificate for biosafety testing

  • Awards

    Selected into the Hang Seng HK 50 Index

    The“Most Honored Company” by Institutional Investor

    2020 Top Graduate Employers Award in China

    CMO Leadership Awards in all six categories (Quality, Reliability, Service, Expertise, Capabilities and Compatibility)

  • History

    March 2019 - Received EMA GMP certificates, the first biologics company in China to pass both the U.S. FDA and EMA inspections.

    April 2019 –Completed the first FDA routine GMP inspection

    June 2019 –Expand the integrated biologics conjugation solution center to include commercial manufacturing.

    August 2019 –The first robotic aseptic filling facility for biologics in China, has achieved GMP release.

    November 2019 - Launch GMP production of ADC drug substance and product in the integrated biologics conjugation solution center.

    November 2019 - WuXi Vaccines build a $240 million manufacturing facility in Ireland.

  • Awards

    “Special Award to Investors in Ireland” from Asia Matters

    CMO Leadership Awards in all six core categories (Quality, Reliability, Service, Expertise, Capabilities and Compatibility)

    “Asia’s Best CMO of 2018” Award from IMAPAC

    “2019 Golden Stock”&“Best IR Award”from ZhiTong Finance and Tonghuashun Finance

    “Best IR Award for Hong Kong Listed Companies (H share)” from New Fortune

  • History

    March 2018 - FDA approved Trogarzo™ (ibalizumab-uiyk), the first HIV-1 inhibitor and long-acting monoclonal antibody for multidrug resistant HIV-1, which was developed by TaiMed Biologics and manufactured by WuXi Biologics.

    April 2018 –WuXi Biologics began global layout (Ireland, Singapore and the U.S.).

    July 2018 –Completed the first cGMP run in MFG3, one of the largest mammalian cell culture capacities in China.

    July 2018- Innovative “scale-out” that instead of “scale-up” approach for large scale manufacturing, successfully proving that combining multiple single-use bioreactors achieved competitive COGS to traditional stainless steel bioreactor facilities.

    December 2018 - Achieved breakthrough titer of 51g/L in cell culture productivity through WuXiUP, a continuous cell culture process with ultra-high productivity.

  • Awards

    SCRIP Award for “Best Company in an Emerging Market”

    Forbes Asia's Best Under A Billion 2018

    “Best Bioprocessing Excellence" and "Bioprocessing Innovations in Continuous Processing Implementation in China” from IMAPAC

    CMO Leadership Award for Reliability from Life Science Leader Magazine

    Selected into the Hang Seng HK 35 Index

    Best IPO Award and Best Investor Relations Award 2017

    Hong Kong Equity Issue from IFR Asia

    Best Block Trade from The Asset

    "2018 Golden Stock”&“Most Valuable Healthcare Stock”from ZhiTong Finance and Tonghuashun Finance

  • History

    June 2017 - Listed on the Hong Kong Stock Exchange and was one of the top ten IPOs on the HKEX for 2017.

    August 2017 - Completed Pre-License Inspection (PLI) conducted by the U.S. FDA at Wuxi cGMP manufacturing facilities for production of ibalizumab.

    August 2017 - WuXi Biologics and Gloria Pharmaceuticals announced the licensure of the fully human PD-1 antibody, GLS-010, to Arcus Biosciences.

    December 2017 - Initiated cGMP manufacturing in the world’s largest biologics manufacturing facility using only single-use bioreactors.

  • Awards

    Asia-Pacific Best Bioprocessing Excellence Award from IMAPAC

    Asia's CMO of 2017 from BioPharma Industry Awards

    Best IPO Award and Best Investor Relations Award 2017 from "Chinese Financial Market"

    2017 Most Popular New Stock from ZhiTong Finance and Tonghuashun Finance

  • History

    January 2016 - WuXi Biologics planned $120 million investment in a new integrated biologics R&D solution center in Shanghai to expedite biologics development from ideas to clinic.

    March 2016 - Became the first company in China to produce biologics for clinical trials in Europe.

    September 2016 - Completed construction of Asia’s largest perfusion biologics manufacturing facility using disposable bioreactors in Wuxi, China.

  • Awards

    Frost & Sullivan “Asia Pacific Biologics CMO Growth Excellence Leadership”

  • History

    April 2015 - Initiated construction of the world’s largest mammalian cell culture manufacturing facility using disposable bioreactors.

    December 2015 - Formed strategic alliance with AstraZeneca to expedite development of AstraZeneca’s innovative biologics portfolio in China.

  • History

    May 2014 - Became the first company in China to manufacture biologics for clinical trials in the U.S.

  • Awards

    Honorable Mention for “Facility of the Year Awards” by ISPE (International Society for Pharmaceutical Engineering)

  • History

    June 2013 – Formed the first innovative antibody drug conjugate development and manufacturing partnership in China with Ambrx and Zhejiang Medicine.

    November 2013 – Completed the first 2,000 L disposable bioreactor run using an NS0 cell line, marking an industry milestone.

  • History

    October 2012 - The Wuxi site was put into operation as the first cGMP biologics manufacturing facility in China.

  • History

    January 2011 – Began mission of providing single-source, open access technology platforms for biologics by building facilities and laboratories in Shanghai and Wuxi for the discovery, development, testing and manufacturing of biologics

  • History

    May 2010 - WuXi Biologics Co., Ltd. was registered in Wuxi city, Jiangsu Province, China.

Business Ethics & IP Policy

WuXi Biologics is committed to the highest possible standards of openness, probity and accountability. Employees, officers and directors strive to deal honestly, ethically and fairly with our suppliers, customers, competitors and employees. Statements regarding the Company’s products and services must not be false, misleading, deceptive or fraudulent. 

In line with that commitment, the Company expects and encourages its employees, customers, suppliers and other stakeholders who have concerns about any suspected misconduct or malpractice within the Company to come forward and voice those concerns through the whistleblowing channel.

Preservation of your IP is our highest priority.
We have established stringent policies and procedures for IP protection and prosecution of IP violations to ensure your success and win your trust.

“Our purpose in business is to enable innovation for our global partners, who keep us at the top of their confidence. IP is our shared lifeline. We guard it at WuXi Biologics with founding principles of integrity, world-class security, zero tolerance policies, and relentless pursuit of justice against any criminal act. This is our highest priority, and we must hold ourselves accountable. We are determined to earn the trust of our partners by committing to success together.”

- Dr. Ge Li, Chairman of WuXi Biologics

Intellectual Property Protection is the foundation of trust between WuXi Biologics and our global customers. To that end, we have established the most stringent policies in China and in U.S. for the protection of intellectual property and for prosecution of IP violations. We guard IP with founding principles of integrity, world-class security, zero-tolerance policy enforcement, and relentless pursuit of justice against any criminal act.


Pioneer and Promote Green Practices

We are dedicated to implementing sustainable and eco-friendly business practices by building a comprehensive and integrated Environmental, Health and Safety (EHS) management system, sourcing ethically, advocating reduced energy consumption, minimizing effluent, and acting responsibly to tackle climate change and reduce operational impact on the environment. 

  • Quality management system certificate

  • Environmental management system certificate

  • Occupational health and safety management system certificate

※ In 2019, Phase I of the Mashan Base, Wuxi Site was awarded the ISO14001 Environmental Management System Certificate.

We adhere to the Three R’s:
Reduce, Reuse, and Recycle
  • Adopt more energy-saving technologies and equipment, such as disposable bioreactors

  • Use water sparingly and reuse for multiple purposes

  • Encourage the use of renewable materials and recycling

  • Reduce greenhouse gas emissions, untreated waste gases and waste discharge. Enforce noise pollution regulations

Give Back to Community

  • Participate in the Protecting Endangered Wild Animals charitable project led by World Animal Protection and become a signatory to the Wild Animal Friendly undertaking as a pharmaceutical enterprise

  • Introduced the science exhibition area to educate on rare and orphan drug diseases and drug development 

  • Organize routine blood donations and actively undertake social responsibility through company-sponsored programs

  • Hold summer Open Access Week events to provide training to better understand the healthcare industry and drug development

Improve Corporate Governance

  • Employee First

  • Corporate Compliance and Anti-Corruption

  • Quality as Foundation

Build a healthy and safe working environment for employees.

Promote a talent development program and sound training system that offers employees promotion opportunities

Offer competitive wages and benefits to foster employees’ sense of belonging and well-being.

Adhere to equal employment opportunity to advance a diverse workforce and to create an equal and inclusive corporate culture

Establish our own compliance management system

“Zero tolerance” for bribery and corruption

Value honesty and trustworthy business conduct

Build a world-class quality system to enable global partners

Establish a 7-step workflow to strictly control every segment

Notice:

You are leaving WuXi Biologics Website, after which our Privacy Notice will not apply. Please keep it in mind the protection of your privacy. Are you willing to proceed?